Starpharma, SSL International Reach Marketing Agreement Over VivaGel Condoms
September 10, 2008
The Australia-based Starpharma on Tuesday announced that its VivaGel-coated condom will be sold by SSL International, the owner of the Durex condom brand, Bloomberg reports. Starpharma expects to earn more than $81 million in royalties and other payments through the deal with SSL. VivaGel is a microbicide designed to prevent the transmission of sexually transmitted infections, including HIV and genital herpes, according to Bloomberg. Starpharma also aims to develop the gel for use on its own as a vaginal microbicide. The agreement provides the rights to sell the VivaGel condom in "most of the world," including Europe and the U.S., Starpharma said in a release (Bennett, Bloomberg, 9/9).
More Effective HIV/AIDS Prevention, Education Efforts Needed to Reach Black, Hispanic Girls, Women, Letter Says
Stigma Deters HIV-Positive People From Seeking Treatment, Panelist Says at Arkansas HIV/AIDS Minority Task Force Meeting
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.